Anaesthesia for Cerebral Aneurysm Clipping

Quick Answer

Cerebral aneurysm clipping requires strict blood pressure control (avoid hypertension pre-clipping, maintain normotension/mild hypotension during dissection), brain relaxation (mannitol, CSF drainage), and readiness for intraoperative rupture (1-5% incidence). Temporary clipping requires neuroprotection (thiopental, etomidate, mild hypothermia 34-35°C) and strict time limits (<10 min optimal, <20 min maximum). Triple-H therapy (hypertension, hypervolemia, haemodilution) for vasospasm is largely abandoned; euvolemia with induced hypertension preferred. Endovascular coiling increasingly replaces clipping for many aneurysms. Anaesthesia: TIVA (propofol/remifentanil) preferred for controlled emergence, avoid hypertension during critical phases, maintain CPP >60 mmHg. [1-10]

Pathophysiology

Aneurysm Characteristics

Types:

• Saccular (berry): 90% of cerebral aneurysms
  • Wall defect at arterial bifurcation (weakness at branching site)
  • Rupture risk depends on size (>7 mm higher risk), location (posterior circulation higher), history of SAH
• Fusiform: Less common, involves circumferential dilation
• Dissecting: Rare, arterial wall dissection

Locations:

• Anterior circulation (85%):
  • Internal carotid artery (30%)
  • Anterior communicating artery (30%) - highest rupture risk
  • Middle cerebral artery (25%)
• Posterior circulation (15%):
  • Basilar tip (highest morbidity if ruptures)
  • Posterior inferior cerebellar artery (PICA)
  • Vertebral artery

Risk Factors for Rupture:

• Size >7 mm (risk increases exponentially >12 mm)
• Location (posterior circulation > anterior)
• Previous SAH
• Hypertension
• Smoking
• Multiple aneurysms
• Familial syndromes (ADPKD, Ehlers-Danlos, Marfan)

Subarachnoid Haemorrhage (SAH)

Grading Systems:

Hunt-Hess Classification:

• Grade I: Asymptomatic, mild headache, normal GCS
• Grade II: Moderate-severe headache, nuchal rigidity, normal GCS
• Grade III: Drowsy, confused, mild focal deficit
• Grade IV: Stuporous, moderate-severe hemiparesis
• Grade V: Coma, decerebrate posturing

WFNS (World Federation of Neurological Surgeons):

• Combines GCS with motor deficit
• Better predictor of outcome

Pathophysiology of SAH:

• Acute ICP rise: Transient (resolves as blood disperses)
• Cerebral vasospasm:
  • Peak incidence: Days 3-14 (peak day 7)
  • Mechanism: Blood breakdown products (oxyhemoglobin) → smooth muscle contraction, inflammation
  • Risk: Delayed cerebral ischemia (DCI)
• Hydrocephalus: Blood obstructs CSF flow (acute or delayed)
• Cardiac dysfunction: Catecholamine surge → Takotsubo cardiomyopathy, ECG changes
• Electrolyte disturbances: Hyponatremia (cerebral salt wasting > SIADH)

Intraoperative Rupture

Incidence: 1-5% (higher in ruptured aneurysms, emergency surgery)

Mechanism:

• Direct surgical manipulation
• Blood pressure surge (laryngoscopy, surgical stimulation)
• Aneurysm fragility

Consequences:

• Massive bleeding (difficult to control)
• Hypotension, hypovolemia
• Brain swelling
• Poor neurological outcome (20-40% mortality if rupture occurs)

Prevention:

• Blood pressure control (avoid hypertension)
• Brain relaxation (reduce retraction pressure)
• Adequate depth before stimulation
• Temporary clipping readiness

Temporary Clipping

Purpose:

• Isolate aneurysm for safe dissection/clipping
• Control bleeding if rupture occurs

Physiological Effects:

• Cerebral ischemia: Territory distal to clip
• Duration critical: <10 minutes (minimal injury), 10-20 minutes (tolerable with protection), >20 minutes (high risk of infarction)

Neuroprotection During Temporary Clipping:

1. Pharmacological:

   • Thiopental: 3-5 mg/kg bolus, then 3-5 mg/kg/hour (burst suppression on EEG)
   • Etomidate: 0.3 mg/kg bolus, then infusion (hemodynamically stable)
   • Propofol: High dose (6-8 mg/kg/hour) - less effective than barbiturates
   • Mechanism: Reduced CMRO₂ (coupled with reduced CBF), metabolic suppression

2. Mild hypothermia:

   • Target: 34-35°C (not routine now, benefit uncertain)
   • Mechanism: Reduces metabolic demand by 7% per degree
   • Risks: Coagulopathy, arrhythmias, shivering, prolonged awakening
   • Evidence: IHAST trial showed no benefit in good-grade SAH

3. Blood pressure augmentation:

   • MAP target: 80-100 mmHg (higher than baseline)
   • Rationale: Maximize collateral flow to ischemic territory
   • Caution: Risk of aneurysm rerupture if temporary clip fails

Cerebral Vasospasm

Timeline:

• Onset: Day 3 post-SAH
• Peak: Days 7-10
• Resolution: Day 14-21

Pathophysiology:

• Blood breakdown products (oxyhemoglobin) in subarachnoid space
• Nitric oxide scavenging (reduces vasodilation)
• Endothelin-1 release (potent vasoconstrictor)
• Inflammatory cascade
• Smooth muscle contraction

Clinical Manifestations:

• Delayed cerebral ischemia (DCI): New focal deficit or decreased consciousness
• Radiographic vasospasm: Angiographic narrowing (may be asymptomatic)
• Symptomatic vasospasm: Clinical deficits correlate with imaging

Monitoring:

• Transcranial Doppler: Velocities >120 cm/s (MCA) suggest vasospasm
  • Lindegaard ratio >3 (MCA velocity / extracranial ICA velocity) confirms vasospasm vs. hyperemia
• CTP: Reduced CBF, increased MTT (mean transit time)
• Angiography: Gold standard (DSA or CTA)

Treatment:

Old: Triple-H Therapy (Abandoned):

• Hypertension, Hypervolemia, Haemodilution
• Risks: Pulmonary oedema, cardiac failure, iatrogenic complications
• Current evidence: Does not improve outcomes, may cause harm

Current: Induced Hypertension + Euvolemia:

• Blood pressure: Systolic 140-180 mmHg (or higher if vasospasm severe)
  • Aim for reversal of neurological deficits
  • May need vasopressors (noradrenaline)
• Volume status: Euvolemia (not hypervolemia)
  • Avoid hypovolemia (reduces CBF)
  • Avoid hypervolemia (pulmonary oedema, cardiac strain)
• Endovascular therapy:
  • Angioplasty (balloon dilation)
  • Intra-arterial vasodilators (nimodipine, verapamil)
  • For refractory vasospasm despite medical therapy

Nimodipine:

• Dose: 60 mg PO/NG q4h for 21 days
• Mechanism: Calcium channel blocker (selective for cerebral vessels)
• Benefit: Reduces DCI by 30-40%, improves outcomes
• Side effects: Hypotension (common), may need dose reduction
• IV form: Not available in Australia (oral/NG only)

Clinical Presentation

Preoperative Assessment

History:

• Presentation: Thunderclap headache (SAH), incidental finding, mass effect (CN III palsy)
• Timing: Days since SAH (vasospasm risk)
• Grade: Hunt-Hess or WFNS grade
• Complications: Hydrocephalus, seizures, cardiac dysfunction
• Comorbidities: Hypertension, smoking, cardiac disease

Physical Examination:

• Neurological: GCS, focal deficits (CN III, hemiparesis), meningismus
• Cardiovascular: BP (baseline for management), ECG changes (T-wave inversions common in SAH)
• Airway: Standard assessment (intubation conditions)

Investigations:

• CT brain: Blood distribution, hydrocephalus, mass effect
• CTA/MRA: Aneurysm location, size, morphology
• Angiography: DSA (gold standard, 3D reconstruction)
• Blood work: FBC, coagulation, electrolytes (hyponatremia common), ECG, troponin (cardiac dysfunction)
• TTE: If cardiac dysfunction suspected

Timing of Surgery:

• Ruptured aneurysms:
  • Early (0-3 days): Prevents rebleeding, but brain swollen
  • Intermediate (4-10 days): Peak vasospasm period (avoid if possible)
  • Late (>10 days): Vasospasm resolving, but risk of rebleed
  • Trend: Early surgery (within 48-72 hours) preferred for good-grade patients
• Unruptured aneurysms: Elective, timing based on risk factors

Management

Anaesthetic Goals

Pre-Clipping (Dissection Phase):

1. Brain relaxation: Mannitol, CSF drainage, head elevation
2. Avoid hypertension: Systolic <140 mmHg (reduces rupture risk)
3. Normocapnia: PaCO₂ 35-40 mmHg
4. Smooth anaesthesia: Avoid BP lability

During Temporary Clipping:

1. Neuroprotection: Thiopental/etomidate (burst suppression)
2. Blood pressure augmentation: MAP 80-100 mmHg (higher than baseline)
3. Monitor EEG: Burst suppression
4. Time limit: <20 minutes (ideally <10)

Post-Clipping:

1. Controlled emergence: Smooth, avoid coughing/straining
2. Blood pressure management: Avoid hypotension (maintain CPP)
3. Neurological assessment: Rapid awakening for examination

Anaesthetic Technique

Premedication:

• Avoid sedation if reduced GCS (masks neurological deterioration)
• If anxious: Short-acting (midazolam 1-2 mg) with caution
• Continue nimodipine: Preoperative dose

Induction:

• Goals: Smooth, controlled, avoid ICP elevation or BP surge
• Technique:
  • Pre-treatment: Lidocaine 1.5 mg/kg IV, additional opioid (fentanyl 2-3 μg/kg or remifentanil bolus)
  • Induction agent: Propofol 2-3 mg/kg (smooth, ↓CBF, ↓ICP) or thiopental 3-5 mg/kg
  • Opioid: Remifentanil infusion (0.1-0.3 μg/kg/min) or fentanyl 3-5 μg/kg
  • Muscle relaxant: Rocuronium (avoid succinylcholine if possible)
  • Laryngoscopy: Ensure adequate depth, minimize stimulation
• Avoid:
  • Ketamine (↑CBF, ↑ICP)
  • N₂O (↑CBF, pneumocephalus risk)
  • Hypertension (rupture risk)

Maintenance:

• TIVA preferred: Propofol (100-200 μg/kg/min) + remifentanil (0.1-0.3 μg/kg/min)
  • Advantages: ↓CBF, rapid emergence, smooth emergence
• Volatile alternative: Sevoflurane <0.5-1 MAC (acceptable if TIVA not available)
• Muscle relaxation: Continuous (rocuronium infusion or intermittent boluses)
• Ventilation:
  • Normocapnia (PaCO₂ 35-40 mmHg)
  • Avoid hypocapnia (ischemia risk during temporary clipping)
  • PEEP 5 cm H₂O (higher may impede venous return)

Monitoring:

• Standard: ECG, SpO₂, NIBP, EtCO₂, temperature
• Arterial line: Essential (continuous BP monitoring, ABGs)
• CVP: Optional (if large fluid shifts anticipated)
• Processed EEG: BIS/Sedline (depth monitoring, burst suppression for temporary clipping)
• Urinary catheter: Fluid balance (mannitol diuresis)
• Temperature: Maintain normothermia (unless hypothermia for temporary clipping - rare now)

Brain Relaxation Strategy

Mannitol:

• Dose: 0.5-1 g/kg IV after dural opening
• Timing: 15-20 minutes before needed
• Monitor: Serum osmolality, urine output

CSF Drainage:

• Lumbar drain: If aneurysm secure and ventricles not obstructed
  • Place preoperatively (lateral position)
  • Drain 50-100 mL before opening dura
  • Risk: Brain herniation if over-drained
• Ventricular drain: If hydrocephalus present

Head Position:

• Elevation: 15-30° (promotes venous drainage)
• Neutral: Avoid rotation/flexion (impedes venous drainage)

Temporary Clipping Protocol

Before Clip Application:

1. Notify anaesthetist: "Placing temporary clip"
2. Check clip time: Synchronize watches
3. EEG baseline: Record pre-clip EEG
4. Blood pressure: Ensure MAP >80 mmHg

During Clipping:

1. Thiopental: 3-5 mg/kg bolus, then 3-5 mg/kg/hour infusion
   • Target: Burst suppression (1-2 bursts/minute)
2. Alternative: Etomidate 0.3 mg/kg bolus, then infusion (more hemodynamically stable)
3. Blood pressure: Maintain MAP 80-100 mmHg (higher than baseline)
4. Monitoring: Continuous EEG (burst suppression), arterial line
5. Communication: Surgeon reports time elapsed q2-3 minutes

If Clip Time >15 Minutes:

• Consider releasing clip briefly (reperfusion) before re-clipping
• This strategy may extend total tolerable ischemic time

After Clip Removal:

1. Stop neuroprotective agent: Lighten anaesthesia
2. Blood pressure: Return to baseline or slightly higher (reperfusion)
3. Assess: Check for bleeding, brain perfusion
4. EEG: Return to normal pattern

Intraoperative Rupture Management

Recognition:

• Sudden blood in surgical field
• Surgeon announces "rupture"
• Hypotension (if significant blood loss)
• Brain swelling

Immediate Response:

1. Anaesthetist actions:

   • Increase FiO₂ to 100%
   • Maintain or slightly lower BP (systolic 90-100 mmHg) to reduce bleeding
   • Prepare for massive transfusion
   • Mannitol if brain swelling

2. Surgeon actions:

   • Suction and temporary clipping (proximal parent vessel)
   • Identify rupture site
   • Place permanent clip if possible
   • Pack with Surgicel if unable to clip immediately

3. Resuscitation:

   • Large bore IV access
   • Blood products if needed (thrombocytopenia, coagulopathy)
   • Vasopressors if hypotensive

4. Post-rupture care:

   • Continue neuroprotection (thiopental)
   • Check coagulation (DIC possible)
   • Plan for ICU admission
   • CT scan postoperatively (check for infarction, residual clot)

Emergence and Postoperative Care

Emergence Goals:

1. Rapid awakening: For immediate neurological assessment
2. Smooth: No coughing, straining (raises ICP, BP)
3. Hemodynamic stability: Avoid hypotension (CPP compromise) and hypertension (vasospasm risk)

Technique:

• Stop remifentanil: 5-10 minutes before emergence (rapid offset)
• Propofol: Reduce infusion, allow clearance
• Reversal: Sugammadex (faster, no anticholinergic side effects vs. neostigmine)
• Lidocaine: 1-5 mg/kg IV (reduces coughing on tube)
• Extubation: Deep (if airway easy) or awake (if difficult)

Blood Pressure Management:

• Target: Baseline or slightly higher (SBP 120-140 mmHg)
• Avoid: Hypertension (>160 mmHg increases vasospasm risk)
• Avoid: Hypotension (<90 mmHg reduces CPP, ischemia risk)
• Agents: Labetalol (if hypertensive), phenylephrine/noradrenaline (if hypotensive)

Postoperative:

• ICU: All SAH patients, high-risk unruptured cases
• Monitoring: Neurological examination q1h, BP control, fluid balance
• Nimodipine: Continue 60 mg q4h for 21 days
• Vasospasm monitoring: TCD daily, clinical assessment
• Hyponatremia: Common (cerebral salt wasting > SIADH), treat with NaCl tablets or 3% saline

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Patients

SAH Incidence:

• Higher rates: Some studies suggest higher incidence in Indigenous populations (hypertension, smoking)
• Risk factors: Higher rates of hypertension, smoking, renal disease (ADPKD association)

Access Issues:

• Geographic barriers: Remote presentation delays diagnosis
• Retrieval challenges: Long transport times to neurosurgical centres
• Timing: May present late, missing early surgery window
• Outcomes: Higher mortality due to delayed treatment, comorbidities

Cultural Considerations:

• Family conferences: Major decisions (surgery vs. coiling, endovascular vs. open)
• Communication: Interpreter services, plain language explanations
• Postoperative support: Challenges with remote follow-up for vasospasm monitoring

Māori Health Considerations

Cardiovascular Risk:

• Higher rates of hypertension (major risk factor for aneurysms)
• Earlier onset of cardiovascular disease
• Smoking rates higher (risk factor for SAH)

Cultural Safety:

• Whānau involvement: Critical for treatment planning
• Bicultural competence: Understanding cultural perspectives on brain injury
• Discharge planning: Support for return to community
• Rehabilitation: Access to culturally appropriate services

ANZCA Final Exam Focus

SAQ Patterns

Common Questions:

• "Describe the anaesthetic management for cerebral aneurysm clipping."
• "How would you manage intraoperative aneurysm rupture?"
• "What neuroprotective strategies are used during temporary clipping?"
• "Explain the pathophysiology and management of cerebral vasospasm."

Marking Scheme Priorities:

• Blood pressure control (pre/during/post-clipping)
• Brain relaxation techniques
• Temporary clipping protocol (neuroprotection, BP augmentation, time limits)
• Intraoperative rupture management
• Vasospasm management (nimodipine, induced hypertension)
• Smooth emergence for neurological assessment

Viva Scenarios

Intraoperative Rupture:

• Sudden hypotension, blood in field
• Immediate management (temporary clip, reduce BP, mannitol)

Temporary Clipping:

• Neuroprotection strategy
• EEG burst suppression
• Time limits

Vasospasm:

• Day 7 SAH patient with new deficit
• Management (induced hypertension, endovascular options)

Key Points for Examination Success

1. Pre-clipping: Avoid hypertension (systolic <140), brain relaxation (mannitol, CSF drain)
2. Temporary clipping: Thiopental/etomidate (burst suppression), MAP 80-100 mmHg, <20 min limit
3. Intraoperative rupture: Temporary clip, reduce BP (SBP 90-100), mannitol, blood products if needed
4. Vasospasm: Nimodipine 60 mg q4h × 21 days, induced hypertension (SBP 140-180), endovascular therapy if refractory
5. Avoid: Triple-H therapy (abandoned), hypervolemia, haemodilution
6. Emergence: Smooth, rapid, avoid coughing, BP control crucial
7. Nimodipine: Must continue for 21 days, PO/NG only in Australia
8. Hyponatremia: Common post-SAH, cerebral salt wasting > SIADH (treat with NaCl)

References

1. ANZCA. PS55. Recommendations on Monitoring During Anaesthesia. 2020.
2. Treggiari MM et al. Anesthesia for cerebral aneurysm surgery. In: Newfield P (ed). Handbook of Neuroanesthesia. 2nd ed. 2012:145-168.
3. Connolly ES et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(6):1711-1737.
4. Todd MM et al. Mild intraoperative hypothermia during surgery for intracranial aneurysm. N Engl J Med. 2005;352(2):135-145. (IHAST trial)
5. Diringer MN et al. Critical care management of patients following aneurysmal subarachnoid haemorrhage. Neurocrit Care. 2011;15(2):211-240.
6. Etminan N et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke. 2023;54(7):e314-e325.
7. MacDonald RL et al. Prevention of vasospasm in subarachnoid hemorrhage. Stroke. 2019;50(12):3583-3590.
8. ATSI Health. Cardiovascular disease in Aboriginal and Torres Strait Islander peoples. Australian Institute of Health and Welfare; 2021.